The Indian Polycap Study (TIPS), presented at the American College of Cardiology (ACC) 2009 Scientific Sessions, has been described as a critical first step to discovering whether a polypill could work effectively. The pill that was used in the study (Polycap) consisted of three antihypertensive drugs, a statin, and aspirin.

Dr Sanjay Kaul talks to study investigator Dr Salim Yusuf about the results of TIPS and the issues around the use of the polypill in a discussion moderated by heartwire's Lisa Nainggolan.

The EARLY ACS trial, presented at the American College of Cardiology 2009 Scientific Sessions, addressed the long-debated question of whether it was better to give GP IIb/IIIa blockers upstream to all high-risk ACS patients or to use them selectively in the cath lab.Incremental new data from the PROTECT-AF study have shown continued efficacy and safety with the Watchman device used to close the left atrial appendage (LAA) as a stroke-prevention strategy in patients with nonvalvular atrial fibrillation.

Drs Melissa Walton-Shirley, Ann Curtis, and Cindy Grines get together in the first all-female panel on theheart.org for an in-depth discussion about the study, including who in the cardiology world will be deploying the device, how it might stand up to new antithrombins, and what effect it will have on atrial-fibrillation ablation rates.

Join Drs Harlan Krumholz, Sanjay Kaul, and Robert Harrington as they review the results of the trial and go into detail about the contentious and sometimes confusing issues surrounding the use of GP IIb/IIIa inhibitors.

he EARLY ACS trial, presented at the American College of Cardiology 2009 Scientific Sessions, addressed the long-debated question of whether it was better to give GP IIb/IIIa blockers upstream to all high-risk ACS patients or to use them selectively in the cath lab.

Join Drs Harlan Krumholz, Sanjay Kaul, and Robert Harrington as they review the results of the trial and go into detail about the contentious and sometimes confusing issues surrounding the use of GP IIb/IIIa inhibitors.

The results of the SYNTAX trial have been hotly debated since they were first presented. The recent analysis of costs and quality-of-life outcomes, presented at the ACC 2009 Scientific Sessions, suggests that CABG-treated patients have more angina relief at one year but that PCI is the more cost-effective strategy, at least in low- and moderate-risk patients. During the first month, quality-of-life analyses clearly favor PCI, but these differences evaporate over the first year. In higher-risk patients, CABG was the clear winner when both costs and lifestyle issues are considered.

Join Drs Robert Harrington, Sanjay Kaul, and Harlan Krumholz for a frank and detailed discussion on the SYNTAX trial, how it has changed what happens in the cath lab, and if and how it should affect guidelines.

In Part 2 of the program, the JUPITER trial is back on the table and our experts give their opinion on the polypill following the results of the TIPS study.

Nine of the world's top cardiologists gathered under thundering skies in Orlando to take on the issues raised by data released at the American College of Cardiology (ACC) 2009 Scientific Sessions.

Dr Valentin Fuster moderates this in-depth and frank discussion between Drs Anne Curtis, Timothy Gardner, Barry Greenberg, Cindy Grines, Bob Harrington, Sanjay Kaul, Harlan Krumholz, and Salim Yusuf.

In Part 2 of the program, the JUPITER trial is back on the table and our experts give their opinion on the polypill following the results of the TIPS study.

Nine of the world's top cardiologists gathered under thundering skies in Orlando to take on the issues raised by data released at the American College of Cardiology (ACC) 2009 Scientific Sessions.

Dr Valentin Fuster moderates this in-depth and frank discussion between Drs Anne Curtis, Timothy Gardner, Barry Greenberg, Cindy Grines, Bob Harrington, Sanjay Kaul, Harlan Krumholz, and Salim Yusuf.

In Part 1 of the program, Fuster asks his expert panel just how surprised they were by the results of the STICH trial and for their comments and concerns about PROTECT-AF